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Abstract: Background: To provide novel insight into the development of new therapeutic strategies to combat breast 
cancer, differentiation-inducing activity of clinically achievable concentrations of arsenite (AsIII) and tetrandrine 
(Tetra) was investigated in breast cancer cell lines MDA-MB-231 and MCF-7. Methods: Differentiation induction 
of cancer cells was analyzed by flow cytometer. Alterations of genes related to differentiation, and proliferation of 
human normal peripheral blood mononuclear cells (PBMCs) were analyzed using western blotting and cell viability 
assay, respectively. Results: Exposure to Tetra alone or in combination with AsIII induced differentiation of both cells 
characterized by upregulation of ICAM-1, downregulation of Her2/neu. In comparison with MCF-7, the combination 
of lower concentrations of AsIII and Tetra induced differentiation of MDA-MB-231, indicating that MDA-MB-231 cells 
were highly susceptible to differentiation. The differentiation occurred in parallel with activation of Erk signaling 
pathway, and was abolished by PD98059, a potent Erk inhibitor. Consistent with in vitro experimental results, the 
upregulation of ICAM-1 and the activation of Erk signaling pathway were also observed in MDA-MB-231 breast 
tumors in xenograft mouse obtained from our previous study. No obvious proliferation inhibition of PBMCs was ob-
served following the exposure to AsIII combined with Tetra at the concentrations capable of inducing differentiation 
of MDA-MB-231 cells. Conclusion: The Erk signaling pathway may be crucially involved in the differentiation induc-
tion of breast cancer cells in vitro and in vivo. Collectively, our results suggest that the combination can probably 
serve as promising candidates for the development of novel therapeutic approaches for different types of breast 
cancer.
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Introduction
Despite advances in early detection, diagnosis, 
and targeted treatment options, breast cancer 
is still the most common cancer among women 
worldwide and persists as one of the leading 
causes of cancer-related deaths in women [1, 
2]. The need for novel therapeutic strategies 
remains paramount given the sustained devel-
opment of drug resistance, tumor recurrence, 
and metastasis [1, 2]. In this regard, remark-
able clinical results achieved with arsenic tri- 
oxide (As2O3, a trivalent arsenic derivative) in 
the treatment of acute promyelocytic leukemia 
(APL) has encouraged more researchers to ex- 
plore its potential treatment application for 
other malignancies, including solid tumors [3, 
4]. Several research groups including us have 
demonstrated that arsenic compounds such as 
trivalent arsenic (arsenite, AsIII) exhibit inhibito-
ry effects against breast cancer cells [5-11]. We 
recently demonstrated a clear cytotoxic effect 
of AsIII against estrogen receptor (ER)-positive 
human breast cancer cell line MCF-7, and fur-
ther clarified that tetrandrine (Tetra), a bis-ben-
zylisoquinoline alkaloid isolated from the root of 
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Stephania tetrandra S. Moore, significantly en- 
hanced the cytotoxicity of AsIII in a synergistic 
manner [7]. In addition, we recently demon-
strated antitumor activity of AsIII in combination 
with Tetra against human triple-negative breast 
cancer (TNBC) cell line MDA-MB-231 in vitro 
and in vivo [8]. These previous findings thus 
raised the possibility of utilizing arsenic com-
pounds to treat patients with breast cancer.
The aim of differentiation therapy is to induce 
the differentiation of malignant cells, conse-
quently cause them to cease proliferation, ulti-
mately control their tumorigenic and malignant 
potential [12, 13]. In general, differentiation 
therapy possesses the obvious characteristics 
of relatively low toxicity compared with conven-
tional chemotherapy [12, 13]. Use of all-trans 
retinoic acid (ATRA) and/or As2O3 in the treat-
ment of APL has acquired a therapeutic niche, 
representing one of the most successful model 
of differentiation therapy [4]. In this respect, we 
have demonstrated that granulocyte colony-
stimulating factor potentiates differentiation 
induction by ATRA and As2O3 and enhances 
arsenic uptake in an APL cell line HT93A [14]. 
We also demonstrated that not only ATRA but 
also valproic acid induced differentiation in 
NB4, another APL cell line, and their combina-
tion further augmented the differentiation ac- 
tivity, in which expression of transcription fac-
tors, CCAAT/enhancer-binding proteins (CEBPα, 
β) and PU.1 were closed involved [15]. More 
recently, we clarified that dasatinib, an inhibitor 
for Src family kinases, enhanced the differenti-
ation-inducing activity of ATRA and dihydroxyvi-
tamin D3 (VD3) in HL-60 cells [16]. Despite this, 
the effect of AsIII and Tetra on breast cancer 
cells in terms of differentiation induction re- 
mains largely unexplored.
In this study, in order to provide novel insights 
into the development of new therapeutic strate-
gies to combat breast cancer using a combined 
regime of AsIII and Tetra, differentiation-induc-
ing activity of the two drugs, each alone or in 
combination, was investigated in two different 
types of human breast cancer cell lines, MDA-
MB-231 and MCF-7. As mentioned above, we 
recently demonstrated that long-term co-ad- 
ministration of AsIII and Tetra significantly redu- 
ced tumor volume and weight in MDA-MB-231 
mouse xenografts [8]. Whether similar differen-
tiation occurred in tumor tissues obtained from 
our previous in vivo study was further investi-
gated in order to confirm the in vitro findings 
of the current study. The effects of AsIII and 
Tetra, each alone or in combination, on the pop-
ulation of CD4+ T cells and CD4+CD25+Foxp3+ 
regulator T (Treg) cells in mitogen-activated hu- 
man normal peripheral blood mononuclear ce- 
lls (PBMCs) were also evaluated, based on the 
fact that Treg cells have been suggested to play 
critical role in limiting antitumor immune re- 
sponse and promoting immunological ignoran- 
ce of cancer cells [17-20].
Materials and methods
Materials
Sodium arsenite (NaAsO2, As
III) and tetrandrine 
(Tetra) were purchased from Tri Chemical 
Laboratories (Yamanashi, Japan) and National 
Institutes for Food and Drug Control (Beijing, 
China), respectively. Fetal bovine serum (FBS) 
was purchased from Nichirei Biosciences (Tok- 
yo, Japan). Dulbecco’s modified Eagle’s medi-
um (DMEM), RPMI-1640 medium, phenazine 
methosulfate (PMS) and dimethyl sulfoxide 
(DMSO) were obtained from Wako Pure Che- 
mical Industries (Osaka, Japan). 2,3-bis(2-me- 
thoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)
carbony]-2H-tetrazolium hydroxide (XTT) were 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Concanavalin A (ConA), a conventionally 
known T-cell mitogen, was obtained from Sei- 
kagaku Kogyo Co., Ltd. (Tokyo, Japan). ERK in- 
hibitor PD98059 was purchased from Calbio- 
chem (La Jolla, CA, USA). Can Get Signal® Im- 
munoreaction Enhancer Solution were pur-
chased from Toyobo Co., Ltd. (Osaka, Japan).  
Cell culture and treatment
Breast cancer cell lines, MDA-MB-231 and 
MCF-7, were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) 
and the RIKEN Cell Bank (Ibaraki, Japan), re- 
spectively. MDA-MB-231 cells were cultured in 
DMEM medium, and MCF-7 cells were cultured 
in RPMI-1640 medium, both of which were sup-
plemented with 10% heat-inactivated FBS and 
100 U/ml of penicillin and 100 µg/ml of strep-
tomycin, in a humidified 5% CO2 atmosphere at 
37°C. PBMCs were isolated from healthy volun-
teers using lymphocyte separation solution 
(d=1.077) (Nakarai Co., Kyoto, Japan) accord-
ing to the method previously described [20, 
21]. Briefly, 3 ml of heparinized blood was load-
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ed on 3 ml of lymphocyte separation solution. 
After centrifugation at 400×g for 30 min at 
room temperature, the opaque interface con-
taining PBMCs was transferred to a clean cen-
trifuge tube and washed three times with PBS. 
PBMCs were also cultured in RPMI-1640 medi-
um supplemented with 10% heat-inactivated 
FBS, 100 U/ml of penicillin and 100 μg/ml of 
streptomycin in a humidified 5% CO2 atmo-
sphere at 37°C. For experiments, the cell den-
sity was adjusted to 5×105 cells/ml prior to the 
treatments. This study has been approved by 
the IRB committee of Tokyo University of Ph- 
armacy and Life Sciences. An informed consent 
was obtained from all healthy volunteers.
Differentiation analysis
Intercellular adhesion molecule-1 (ICAM-1), al- 
so referred to as CD54, is a cell surface glyco-
protein member of the immunoglobulin super-
family responsible for regulating cell/cell con-
tacts [22]. It is also known as a differentiation 
marker which is present in normal mammary 
epithelium but frequently downregulated in 
breast cancer cells [23]. Immunohistochemical 
examination of resected tumors from female 
patients with invasive breast cancer revealed 
that ICAM-1 expression had negative correla-
tion to tumor size and infiltration, and that 
patients with ICAM-1 positive tumors had bet-
ter relapse-free and overall survival than those 
with negative tumors [24]. The expression level 
of ICAM-1 was assessed using a FACSCanto 
flow cytometer (Becton Dickinson, San Jose, 
CA, USA) according to a method previously de- 
scribed with slight modifications [25, 26]. Brie- 
fly, after the treatment with various concentra-
tions of AsIII and Tetra, alone or in combination, 
for 96 h, ~1×106 cells were collected and wa- 
shed once with PBS (pH 7.4) (Gibco®; Thermo 
Fisher Scientific, Waltham, MA, USA), followed 
by the addition of 10 μl of monoclonal mouse 
anti-human CD54 PE-conjugated antibody (Bio- 
Legend San Diego, CA, USA). After the incuba-
tion for 20 min in the dark at 37°C, the cells 
were washed with PBS and resuspended in 0.4 
ml staining buffer [0.4% (v/v) formaldehyde 
neutral buffer solution in PBS (pH 7.4); Nacalai 
Tesque, Inc., Kyoto, Japan], and then analyzed 
by flow cytometry. The results were shown as 
mean fluorescence intensity (MFI) with linear 
scaling and calculated by subtracting the mean 
fluorescence of the unstained cells from that of 
the stained cells, as described previously [15, 
16, 27]. In order to evaluate the correlation 
between the activation of Erk and the differen-
tiation induced by AsIII and Tetra, breast cancer 
cell lines were treated with 10 µM PD98059 for 
30 min prior to the treatment with various con-
centrations of AsIII and Tetra, alone or in combi-
nation, in the presence or absence of 10 µM 
PD98059 for an additional 96 h, followed by 
differentiation analysis as described above.
Proliferation assay of PBMCs
The effect of AsIII and Tetra, alone or in combi-
nation, on the proliferation of PBMCs was mea-
sured by XTT dye-reduction assay according to 
the method previously described with slight 
modifications [7, 8, 21]. Briefly, PBMCs was 
adjusted to 5×105 cells/ml, and 186 μl of the 
cell suspension was inoculated into 96-well 
plates, followed by the addition of 10 μl of ConA 
(0.1 mg/ml in PBS) at final concentrations of 
5.0 μg/ml. Subsequently, 4 μl of each drug or 
their combination solution was added to give 
final indicated concentrations. Cells in sixpli-
cate were treated with various concentrations 
of AsIII and Tetra, alone or in combination, for 72 
h. Following the treatment, XTT and PMS were 
added into each well at final concentrations of 
0.2 mg/ml and 1 mM, respectively. After incu-
bation at 37°C for 4 h, the plates were mixed 
and the absorbance at 450 nm was measured 
with a microplate reader (EMax Plus®, Mole- 
cular Devices, CA, USA). The relative cell viabil-
ity was expressed as the ratio of the absor-
bance of each treatment group against those of 
the corresponding untreated control group. 
Data are shown as means ± standard deviation 
(SD) from more than three independent expe- 
riments.
Analysis of CD4+ T cells and Treg cells
After treatment with 0.5 μM AsIII, 0.5 μg/ml 
Tetra, each alone or in combination, for 72 h, 
alterations of CD4+ T cells and Treg cells popu-
lation in mitogen-activated PBMCs were ana-
lyzed using a FACSCalibur™ II flow cytometer 
(BD Biosciences, Mountain View, CA, USA) ac- 
cording to the method previously described 
with slight modifications [19, 20]. Briefly, after 
treatment with the two drugs, ~1×106 cells we- 
re collected and washed once with PBS (pH 7.4) 
(Gibco®; Thermo Fisher Scientific, Waltham, 
MA, USA), followed by the addition of 10 μl of 
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monoclonal mouse anti-human CD4 PerCP- 
Cy5.5-conjugated antibody and 10 μl of mono-
clonal mouse anti-human CD25 PE-conjugated 
antibody (BD Biosciences), respectively. To ex- 
clude the amount of non-specific binding, 10 μl 
of PerCP-Cy5.5-conjugated and 10 μl of PE- 
conjugated mouse IgG1 κ isotype control (BD 
Biosciences) were used and evaluated as back-
ground, respectively. After the incubation for 
20 min in the dark at 37°C, the cells were wa- 
shed with PBS and resuspended in diluted 
Foxp3 buffer A (BD Biosciences), followed by 
the incubation for 10 min in the dark at room 
temperature. Then, the cells were washed once 
with PBS and resuspended in 0.2 ml of Foxp3 
buffer C composed of 49 parts Foxp3 buffer A 
and 1 part Foxp3 buffer B (BD Biosciences), 
and incubated for 30 min in the dark at room 
temperature. After the incubation, the cells 
were washed once with PBS and 10 μl of mouse 
anti-human Foxp3 Alexa Fluor® 488-conjugat-
ed antibody or 10 μl of Alexa Fluor® 488-conju-
gated mouse IgG1 isotype control to re-sus-
pend the pellet was added, and incubation for 
30 min in the dark at 37°C followed. After 
washing once with PBS, the cells were resus-
pended in 0.4 ml staining buffer [0.4% (v/v) 
formaldehyde neutral buffer solution in PBS 
(pH 7.4); Nacalai Tesque, Inc., Kyoto, Japan] 
and analyzed by flow cytometry, and then the 
data were further analyzed using CellQuest 
software (BD Biosciences). CD4+ T cells in the 
lymphocyte fraction were gated, and the per-
centages of CD4+ T cells and Treg cells in the 
CD4+ T cells were calculated, respectively.  
Western blot analysis
For protein samples preparation, cell pellets 
(approximately 1-2×106 cells per 110 μl Laem- 
mli buffer) were suspended in lysis buffer (La- 
emmli buffer containing 100 mM DTT, 2 μg/ml 
leupeptin, 2 μg/ml aprotinin, 1 μg/ml pepes- 
tain, 1 mM PMSF). The suspensions of cells we- 
re sonicated using a sonicator (Qsonica, LLC, 
CT, USA) with 10 short bursts of 2 sec followed 
by intervals of 2 sec for cooling. The suspen-
sions were kept at all times in an ice bath. 
Sonicated cells were heated in 95°C for 5 min, 
and then centrifuged at 13,000 g for 15 min at 
4°C. Protein concentrations of the supernatant 
were determined according to Bradford’s meth-
od using the protein assay dye reagent (Bio-
Rad, CA, USA) according to the manufacturer’s 
instructions, and using BSA as the standard. 
Western blot analysis was carried out accord-
ing to the methods previously described [28]. 
Briefly, after separation of proteins on a sodium 
dodecyl sulfate (SDS) polyacrylamide gel elec-
trophoresis, followed by transferring to a polyvi-
nylidene difluoride (PVDF) membrane (Millipore 
Corp, MA, USA), protein bands were detected 
using the following primary antibodies and dilu-
tion ratios: mouse anti-human β-actin (1:5000 
dilution; cat. no. A-5441; Sigma-Aldrich, MO, 
USA), mouse anti-human ICAM-1 (G-5) (1:1000 
dilution; cat. no. sc-8439; Santa Cruz Biote- 
chnology, CA, USA), rabbit anti-human HER2/
ErbB2 (29D8) (1:1000 dilution; cat. no. 2165), 
rabbit anti-human phospho-p44/42 MAPK (Er- 
k1/2) (Thr202/Tyr204) (1:2000 dilution; cat. 
no. 4695) and p44/42 MAPK (Erk1/2) (137F5) 
(1:1000 dilution; cat. no. 4370) (Cell Signaling 
Technology, MA, USA). Blotted protein bands 
were detected with respective horseradish per-
oxidase-conjugated secondary antibody and an 
enhanced chemiluminescence (ECL) Western 
blot analysis system (Amersham Pharmacia 
Biotech, Buckinghamshire, UK). In order to con-
firm the in vitro findings of the current study, the 
alteration of the expression levels of ICAM-1, 
phospho-Erk and Erk was also evaluated in pre-
vious stocked tumor tissues obtained from 
MDA-MB-231 mouse xenografts, which have 
been used to clarify that co-administration of 
AsIII and Tetra significantly reduced tumor vol-
ume and weight in the mouse xenografts in our 
previous in vivo study [8]. Similarly to the pro-
tein samples preparation from cancer cell lines, 
the previous stocked tumor tissues (at a ratio of 
approximately 1 g of tissue per 10 ml Laemmli 
buffer) obtained from MDA-MB-231 mouse 
xenografts were also suspended in lysis buffer, 
and then sonicated, followed by the same pro-
cedures described as above.  
Statistical analysis
Experiments were independently repeated th- 
ree times, and the results are presented as the 
means ± standard deviation (SD) of the three 
assays. Statistical analysis was performed us- 
ing GraphPad Prism® 6 software. The Student’s 
t-test was used to compare sample means be- 
tween two groups, and one-way analysis of vari-
ance followed by Dunnett’s post hoc test was 
used to compare sample means among three 
or more groups. A probability level of P<0.05 
was considered statistically significant.
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Results
Induction of the expression of ICAM-1 in breast 
cancer cells treated with AsIII and Tetra, alone 
or in combination
ICAM-1 has been identified and used as a mar- 
ker of differentiation for human mammary epi-
thelial cells and human breast cancer cells in 
several studies [25, 26, 29, 30]. Furthermore, 
ATRA, which has been successfully used as a 
differentiation agent in the treatment of APL, 
has been reported to induce differentiation of 
human breast cancer cell lines by upregulating 
ICAM-1 expression [26]. Consistent with the 
previous report, both flow cytometry (FCM) and 
western blot (WB) analysis demonstrated that 
1 μM ATRA, served as positive control in the 
current study, prominently upregulated the 
expression of ICAM-1 in MDA-MB-231 cells 
(Figures 1A, 1C and 2A), although similar phe-
nomena were not observed in MCF-7 cells 
(Figures 1B, 1D and 2B).  
Since it has been established that the plasma 
concentrations of AsIII were generally believed 
to be maintained between 0.1-2 μM in APL 
patients treated with As2O3 [4], clinically achiev-
able concentrations of AsIII (under 2 μM) were 
used throughout the study. As shown in Figures 
1A, 1C and 2A, FCM results showed that rela-
tively high concentrations of Tetra (0.5, 1 and 2 
μg/ml) slightly but significantly induced the 
expression of ICAM-1 in MDA-MB-231 cells, 
which is in good agreement with the WB experi-
mental results, indicating its differentiation-
inducing activity in the cells. Whereas almost 
no alteration of ICAM-1 expression was 
observed in the cells treated with different con-
centrations of AsIII regardless of analytical app- 
roaches. Intriguingly, both FCM and WB results 
showed that the combination of relatively low 
concentrations of AsIII and Tetra, especially 
0.25 μM AsIII+0.25 μg/ml Tetra, slightly but sig-
nificantly upregulated the expression level of 
ICAM-1, although similar upregulation was not 
observed in the cells when treated with either 
drug alone. In contrast, the combination of 1 
μM AsIII+1 μg/ml Tetra failed to upregulate the 
expression level of ICAM-1 in MDA-MB-231 
cells, although 1 μg/ml Tetra alone exhibited 
activity to induce ICAM-1 expression. In addi-
tion, exposure to the combination of the high-
est concentrations of 2 μM AsIII+2 μg/ml Tetra 
resulted in a significant downregulation of the 
expression of ICAM-1, which might be attribut-
ed to the cytotoxicity of the long-term combina-
tion treatment.  
In comparison with MDA-MB-231 cells, only the 
highest concentrations of AsIII (2 μM) and Tetra 
(2 μg/ml) alone upregulated the expression 
level of ICAM-1 in MCF-7 cells (Figures 1B, 1D 
and 2B). FCM results also demonstrated that 
the combination of relatively high concentra-
tions of AsIII and Tetra (1 μM AsIII+1 μg/ml Tetra 
and 2 μM AsIII+2 μg/ml Tetra) slightly but signifi-
cantly upregulated the expression level of 
ICAM-1 when compared to control group and 
each drug alone (Figure 1B and 1D), which we- 
re largely consistent with WB results (Figure 
2B), indicating that the two drugs exhibit a 
stronger differentiation-inducing activity than 
ATRA in MCF-7 cells.  
Effects of AsIII and Tetra, alone or in combina-
tion, on the expression level of Her2/neu and 
the activation of Erk pathway in breast cancer 
cells
Downregulation of human epidermal growth 
factor receptor type 2 (Her2/neu) has been 
reported to be associated with differentiation 
of breast cancer cells including MCF-7 [31, 32]. 
As shown in Figure 2A, consistent with the al- 
teration profiles of ICAM-1, a clear dose-depen-
dent decrease in the expression level of Her2/
neu was observed in MDA-MB-231 treated with 
Tetra, especially at its relatively high concentra-
tions of 1 and 2 μg/ml. Similarly, the expression 
of Her2/neu was also reduced by approximate 
40% following the combinatorial treatment with 
0.25 μM AsIII+0.25 μg/ml Tetra. On the other 
hand, a slight downregulation of Her2/neu ex- 
pression was observed in the cells after treat-
ment with relatively low, but not high concen-
trations of AsIII, which might not be directly lin- 
ked to differentiation. In the case of MCF-7, as 
shown in Figure 2B, the expression level of 
Her2/neu was downregulated by approximately 
20-30% following the treatment with 2 μg/ml 
Tetra, and the combination of two drugs (1 μM 
AsIII+1 μg/ml Tetra and 2 μM AsIII+2 μg/ml 
Tetra), almost in parallel with the alteration pro-
files of ICAM-1.  
In addition, extracellular-regulated kinase (Erk) 
signaling pathway has been demonstrated to 
be involved in the differentiation of human 
breast cancer cells [32, 33]. As shown in Figure 
2, the expression levels of phosphorylated Erk 
(phospho-Erk) were obviously upregulated by 
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the treatment with AsIII and Te- 
tra, each alone or in combina-
tion, at the concentrations of 
which significantly upregulated 
the expression levels of ICAM-
1 in both breast cancer cells, 
indicating the activation of Erk 
signaling pathway. In accordan- 
ce with the upregulation of ph- 
ospho-Erk, a slight downregu-
lation of total-Erk was also ob- 
served in MDA-MB-231 cells 
(Figure 2A).
Upregulation of ICAM-1 and 
activation of Erk signaling 
pathway in MDA-MB-231 
mouse xenografts treated with 
AsIII and Tetra, alone or in com-
bination
We recently demonstrated gro- 
wth inhibition of MDA-MB- 
231 by AsIII and Tetra in vitro 
and in vivo, in which long-term 
(10 weeks) co-administration 
of AsIII (2 mg/kg/day) and Tetra 
(20 mg/kg/day) significantly re- 
duced tumor volume and weig- 
ht, directly supporting their in 
vitro antitumor activity [8]. In 
order to explore whether differ-
entiation is also involved in the 
tumor growth inhibition in vivo, 
the expression levels of ICAM-
1, phospho-Erk as well as total 
Erk were evaluated in previous 
stocked tumor tissues obtain- 
ed from the above-mentioned 
MDA-MB-231 mouse xenogra- 
fts. As shown in Figure 3A and 
3B, in comparison with vehicle-
control group, a significant up- 
Figure 1. Induction of the expression of ICAM-1 in breast cancer cells treated with AsIII and Tetra, alone or in combi-
nation. The expression level of ICAM-1 was determined using a FACSCanto flow cytometer after the treatment with 
various concentrations of AsIII alone (0.125, 0.25, 0.5, 1 and 2 µM), Tetra alone (0.125, 0.25, 0.5, 1 and 2 µg/
ml), their combination in constant ratio (0.125 µM AsIII+0.125 µg/ml Tetra, 0.25 µM AsIII+0.25 µg/ml Tetra, 0.5 µM 
AsIII+0.5 µg/ml Tetra, 1 µM AsIII+1 µg/ml Tetra and 2 µM AsIII+2 µg/ml Tetra) for 96 h. The expression levels of ICAM-
1 in breast cancer cells were analyzed and presented as histograms plotted by FACS as described in methods sec-
tion. Representative FACS histograms of ICAM-1 expression in MDA-MB-231 (A) and MCF-7 (B) are shown. Untreated 
and treated cells are represented by filled histograms and open histograms, respectively. Relative expression levels 
of ICAM-1 in MDA-MB-231 cells (C) and MCF-7 cells (D) were calculated, respectively, based on FACS profiles shown 
in (A) and (B). Experiments were independently repeated at least three times and results are shown as means ± SD. 
*, P<0.05 vs. control; #, P<0.05 vs. each alone. As, AsIII; Tetra, tetrandrine; ATRA, all-trans retinoic acid. MFI mean 
fluorescence intensity. ATRA (1 µM) used as a positive control for differentiation.
Figure 2. Expression profile of differentiation-related proteins in breast can-
cer cells treated with AsIII and Tetra, alone or in combination. After treat-
ment with indicated concentrations of AsIII and Tetra, alone or in combina-
tion, for 96 h, the expression profiles of differentiation-related proteins in 
MDA-MB-231 cells (A) and MCF-7 cells (B) were analyzed using western blot 
as described in material and methods. Representative image of the expres-
sion profile of each protein is shown from three independent experiments. 
The densitometry of protein bands was analyzed using a program, NIH Im-
ageJ 1.52a. The values above each image represent the ratios between 
each key molecule and β-actin protein expression levels, which were further 
compared with those of control group (untreated cells). p-Erk, phosphory-
lated Erk; As, AsIII; Tetra, tetrandrine; ATRA, all-trans retinoic acid. ATRA (1 
µM) used as a positive control for differentiation.
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regulation of ICAM-1 was observed in the iso-
lated tumors derived from mice treated with 
either drug alone or their combination. Intrigui- 
ngly, alteration of phospho-Erk/Erk ratio was 
further strengthened by the combination as 
compared to either drug alone, indicating the 
activation of Erk signaling pathway (Figure 3A 
and 3C).
Effect of PD98059 on the expression profile of 
ICAM-1 induced by AsIII and Tetra, alone or in 
combination, in breast cancer cells
In order to clarify the correlation between the 
activation of Erk signaling pathway and the dif-
ferentiation of breast cancer cells, the effect of 
PD98059, a potent Erk inhibitor, on the expres-
sion level of ICAM-1 induced by AsIII and Tetra 
was further investigated. Considering the con-
cept of minimizing the side effects of AsIII, and 
the capacity of two drugs to induce differentia-
sion triggered by 2 μM AsIII and 2 μg/ml Tetra, 
each alone or in combination, was also obvi-
ously reversed by the addition of PD98059 in 
MCF-7 cells (Figure 4B).  
Effect of AsIII and Tetra, each alone or in com-
bination, on the proliferation of PBMCs 
As shown in Figure 5, an approximately 20% 
proliferation inhibition of PBMCs was observed 
following exposure to various concentrations of 
AsIII (0.125-2 μM) alone for 72 h, reflecting its 
good tolerance in clinical use. Moreover, almost 
no proliferation inhibition was observed in the 
cells after treatment with a relatively low con-
centration of Tetra (0.125-0.5 μg/ml), whereas 
a considerable inhibitory effect of a relatively 
high concentration of Terta (1 and 2 μg/ml) was 
observed. Of note, the combination of a rela-
tively low concentration of the two drugs (0.125 
μM AsIII+0.125 μg/ml Tetra, 0.25 μM AsIII+0.25 
Figure 3. Upregulation of ICAM-1 and activation of Erk signaling pathway in 
MDA-MB-231 mouse xenografts treated with AsIII and Tetra, alone or in com-
bination. MDA-MB-231 tumors in the mice xenograft model treated with AsIII 
and Tetra, alone or in combination, were obtained from our previous study, 
in which long-term (10 weeks) co-administration of AsIII (2 mg/kg/day) and 
Tetra (20 mg/kg/day) significantly reduced tumor volume and weight [8]. 
(A) The expression profiles of ICAM-1, phospho-Erk and total Erk were ana-
lyzed using western blot as described in material and methods. Results are 
representatives of three independent experiments. The relative expression 
levels of ICAM-1 (B) and phospho-Erk/Erk (C) were expressed as the ratios 
between each target gene protein and β-actin protein expression levels, 
and compared with those of untreated control group, respectively. Results 
are shown as the means ± SD from three independent experiments. p-Erk, 
phosphorylated Erk; As, AsIII; Tetra, tetrandrine. The procedures for estab-
lishment of MDA-MB-231 mouse xenografts, and the following administra-
tion of AsIII and Tetra, each alone or in combination, and the preparation of 
tumor tissues are shown in Supplementary Materials. 
tion in different breast cancer 
cells, differential concentrati- 
ons of AsIII and Tetra were us- 
ed. As shown in Figure 4A, sim-
ilar to the results in Figure 1C, 
exposure to the combination of 
0.25 μM AsIII+0.25 μg/ml Tetra 
and 1 μg/ml Tetra significantly 
upregulated ICAM-1 expressi- 
on in MDA-MB-231 cells, res- 
pectively. The upregulation of 
ICAM-1 was also observed in 
the cells when treated with 
0.25 μg/ml Tetra alone, where-
as there was only a modest 
upregulation of ICAM-1 follow-
ing the same treatment in 
Figure 1C, the slight discrep-
ancy of which might be attrib-
uted to batch cultures. Of note, 
the addition of PD98059 com-
pletely abrogated the upregula-
tion of ICAM-1 triggered by the 
two drugs. Intriguingly, the ad- 
dition of PD98059 also result-
ed in a slight but significant 
downregulation of endogenous 
level of ICAM-1 in MDA-MB-231 
cells, indicating the critical role 
of Erk signaling pathway in reg-
ulating ICAM-1 expression. Si- 
milar to MDA-MB-231 cells, the 
upregulation of ICAM-1 expres-
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μg/ml Tetra, 0.5 μM AsIII+0.5 μg/ml Tetra) did 
not result in a clear proliferation inhibition, indi-
cating that Tetra was capable of reversing the 
inhibitory effect of AsIII on PBMCs. On the other 
hand, approximately 30% and 60% prolifera-
tion inhibition of PBMCs were observed follow-
ing the exposure to the combination of 1 μM 
AsIII+1 μg/ml Tetra and 2 μM AsIII+2 μg/ml Te- 
tra, respectively.  
Effects of AsIII and Tetra, each alone or in com-
bination, on the populations of CD4+ T cells 
and Treg cells in mitogen-activated human 
PBMCs
The populations of CD4+ T cells and Treg cells in 
mitogen-activated human PBMCs were ana-
lyzed by flow cytometry following the treatment 
with two drugs for 72 h. In the experiment, 0.5 
μM AsIII and 0.5 μg/ml Tetra were selected 
since each of them are their respective highest 
concentrations with limited or no proliferation 
inhibition, and their combination exhibited no 
obvious cytotoxicity against PBMCs (Figure 5). 
As shown in Figure 6B and 6C, exposure to 0.5 
μg/ml Tetra tended to decrease the population 
of Treg cells, whereas 0.5 μM AsIII had little 
effect in this respect. Similar to the effect of 
Tetra alone, a slight downregulation of the pop-
ulation of Treg cell was also observed when 
treated with the combination of 0.5 μM AsIII+0.5 
μg/ml Tetra, although the changes were not 
statistically significant. On the other hand, no 
influence of two drugs, each alone or in combi-
nation, on the population of CD4+ T cells was 
observed (Figure 6D). 
Discussion 
Previous studies have demonstrated that cer-
tain chemicals such as ATRA and VD3 are capa-
ble of inducing the differentiation of malignant 
cells, consequently causing them to cease pro-
liferation instead of killing them through cyto-
toxicity [4, 14-16]. Generally, differentiation the- 
rapy possesses the obvious characteristics of 
Figure 4. Effect of PD98059 on the expression profile of ICAM-1 induced by AsIII and Tetra, alone or in combination, 
in breast cancer cells. After treatment with indicated concentrations of AsIII and Tetra, alone or in combination, in 
the presence or absence of 10 μM PD98059, for 96 h, the expression profiles of ICAM-1 were determined using 
a FACSCanto flow cytometer as described in material and methods. Relative expression levels of ICAM-1 in MDA-
MB-231 (A) and MCF-7 (B) were calculated based on their respective FACS profiles. *, P<0.01, **, P<0.0001 vs. 
control; †, P<0.05, ††, P<0.001, †††, P<0.0001 group with PD98059 vs. respective group without PD98059; #, 
P<0.001 vs. each alone. As, AsIII; Tetra, tetrandrine.
Figure 5. Effects of AsIII and Tetra, alone or in com-
bination, on the proliferation of PBMCs. Follow-
ing the treatment with various concentrations of 
AsIII alone (0.125, 0.25, 0.5, 1, 2 μM), Tetra alone 
(0.125, 0.25, 0.5, 1, 2 μg/mL), or their combination 
(0.125 μM+0.125 μg/mL, 0.25 μM+0.25 μg/mL, 0.5 
μM+0.5 μg/mL, 1 μM+1 μg/mL, 2 μM+2 μg/mL) for 
72 h, cell viability was determined by XTT assay as 
described under materials and methods. Relative 
cell viability was calculated as the ratio of the absor-
bance at 450 nm of each treatment group against 
those of the corresponding untreated control group. 
Data are shown as the means ± SD from more than 
three independent experiments. *P<0.05, vs con-
trol. As, AsIII; Tetra, tetrandrine.
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Figure 6. Effects of AsIII and Tetra, each alone or in combination, on the population of CD4+ T cells and Treg cells in mitogen-activated human PBMCs. After treatment 
with 0.5 μM AsIII and 0.5 μg/ml Tetra, alone or in combination, for 72 h, alterations of CD4+ T cell and Treg cell populations in ConA-activated PBMCs were analyzed 
by a flow cytometer as described in materials and methods. (A) Lymphocyte fraction of PBMCs (a1) were gated for CD4+ T cells (a2), and the percentage of Treg cells 
in the CD4+ T cells fraction in each treatment were calculated (B). Treg cells (C) and CD4+ T cells (D) in ConA-activated PBMCs treated with 0.5 μM AsIII and 0.5 μg/
ml Tetra, alone or in combination, for 72 h were calculated, respectively. Data are presented as means ± SD from more than three independent experiments. As, 
AsIII; Tetra, tetrandrine.
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relatively low toxicity compared with conven-
tional chemotherapy [12, 13]. Although the dif-
ferentiation-inducing activity of Tetra has been 
demonstrated in leukemic cells [34, 35], whe- 
ther differentiation induction occurs in breast 
cancer cells has not yet been investigated. 
Results from this study demonstrated for the 
first time that relatively high concentrations of 
Tetra (>0.5 μg/ml) alone clearly induced differ-
entiation in different types of breast cancer 
cells regardless of their estrogen dependency, 
as evidenced by the upregulation of ICAM-1 and 
downregulation of Her2/neu proteins. Indeed, 
similar alterations of both ICAM-1 and Her2/
neu proteins have been reported to be associ-
ated with differentiation of human breast can-
cer cells [25, 26, 29-32]. Consistent with the 
findings in the current study, previous reports 
also showed that similar concentrations (2 μg/
ml) of Tetra forced leukemic cells including 
HL-60, NB4 and K562 to differentiate [34, 35]. 
In comparison to previous report showing 0.5 
μM arsenic trioxide (As2O3) induced differentia-
tion of breast cancer cell lines including MDA-
MB-231 and MCF-7 [25], obvious features of 
differentiation were not observed in the current 
study. The discrepancy might be explained by 
the following facts: 1) NaAsO2 was used in the 
current study, while As2O3 was used in the pre-
vious study, 2) different sources of breast can-
cer cells in two researches. In fact, the breast 
cancer cells used in the previous study were 
obtained from ATCC, whereas in the current 
study MCF-7 were obtained from the RIKEN Cell 
Bank (Ibaraki, Japan). In agreement with the pre- 
vious report [25], our in vivo study experimen-
tally demonstrated that long-term administra-
tion of AsIII induced differentiation of tumor tis-
sue obtained from previous stocked MDA-
MB-231 mouse xenografts, suggesting its dif-
ferentiation-inducing activity in vivo.
We further demonstrated that exposure to the 
combination of AsIII and Tetra at their respec-
tive clinically acceptable concentrations indu- 
ced differentiation in both cancer cells. Again, 
the combination-triggered differentiation was 
also confirmed in tumor tissues in MDA-MB-231 
mouse xenografts, suggesting that two drugs-
mediated differentiation partially contributed 
to the achievement of long-term co-administra-
tion of AsIII and Tetra to reduce tumor volume 
and weight in our recent report [8]. Of note, the 
combination of relatively low concentrations of 
AsIII and Tetra (0.25 μM AsIII+0.25 μg/ml Tetra) 
significantly induced differentiation in MDA-
MB-231 cells.  In comparison, only relatively hi- 
gh concentrations of two drugs (1 μM AsIII+1 
μg/ml Tetra and 2 μM AsIII+2 μg/ml Tetra) exhib-
ited similar differentiation-inducing activity in 
MCF-7, suggesting that MDA-MB-231, known 
as a TNBC cell line, were highly susceptible to 
differentiation. Considering TNBC is one of the 
most difficult subtypes of breast cancer to treat 
due to its aggressive, metastatic behavior, and 
a lack of a targeted therapy [36], the combina-
tion of AsIII and Tetra, which have long been suc-
cessfully used in clinic, can probably serve as 
promising candidates to differentiate cancer 
cells, ultimately cease their uncontrolled prolif-
eration in patients with TNBC. Previous studies 
have demonstrated that VES, a derivate of vita-
min E (RRR-α-tocopheryl) induced differentia-
tion in human breast cancer cells including 
MCF-7 in parallel with the downregulation of 
Her2/neu [31, 32]. Furthermore, it has been 
clarified that antibodies reacting with Her2/neu 
receptor can induce differentiation of human 
breast cancer cells [31, 37]. In agreement with 
these previous reports, following exposure to 
the combination of AsIII and Tetra, a clear down-
regulation of Her2/neu protein was observed in 
MDA-MB-231 as well as MCF-7 cells. In addi-
tion, it has been demonstrated that the ability 
of VES to induce MCF-7 cells differentiation 
does depend on Erk signaling pathway, based 
on the fact that the addition of PD98059 
blocked the differentiation-inducing activity of 
VES [32]. Similarly, Liu et al. also demonstrated 
that the activation of Erk signaling pathway was 
involved in genistein-induced differentiation of 
breast cancer stem/progenitor cells [33]. In 
line with previous reports, coincidentally with 
differentiation induction, the activation of Erk 
signaling pathway was observed in MDA-MB- 
231, MCF-7 cells as well as tumor tissue derived 
from MDA-MB-231 mouse xenografts following 
the treatment with the combination of AsIII and 
Tetra. Additionally, the differentiation of both 
cancer cells was significantly reversed by the 
addition of PD98059, suggesting the critical 
role of Erk signaling pathway in the differentia-
tion induction.  
We also demonstrated no obvious proliferation 
inhibition of PBMCs following the exposure to 
the combination of AsIII and Tetra (0.125 μM 
AsIII+0.125 μg/ml Tetra, 0.25 μM AsIII+0.25 μg/
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ml Tetra, 0.5 μM AsIII+0.5 μg/ml Tetra) for 72 h, 
which clearly induced differentiation of MDA-
MB-231 cells. In clinic, the plasma concentra-
tions of AsIII were generally believed to be main-
tained between 0.1-2 μM in APL patients treat-
ed with As2O3 [4]. Collectively, these results 
suggest the potential therapeutic efficacy of 
the combination to patients with TNBC. Our 
results also showed a slight downregulation of 
the population of Treg cells following treatment 
with 0.5 μM AsIII combined with 0.5 μg/ml Tetra, 
consistent with our recent report [38]. Given 
that Treg cells play a critical role in tumor immu-
notolerance by suppressing antitumor immuni-
ty [17, 18, 39], the clinic use of Tetra, as an ad- 
juvant therapeutic agent, might provide bene-
fits to patients treated with AsIII, although accu-
rate effects of the combination on the popula-
tion of Treg cells warrants further investigation 
in a breast cancer xenograft model.
Conclusions
Our results demonstrated that clinically achiev-
able concentrations of AsIII combined with Tetra 
clearly induced differentiation in different types 
of breast cancer cells regardless of their estro-
gen dependency, and that MDA-MB-231 cells 
were more susceptible to differentiation than 
MCF-7 cells. Although further investigations are 
needed to clarify the mechanisms underlying 
the differentiation, our results suggest that the 
activation of Erk signaling pathway and down-
regulation of Her2/neu are closely implicated in 
the differentiation. We further demonstrated th- 
at exposure to the two drugs at the concentra-
tions inducing differentiation of MDA-MB-231 
cells did not result in a clear proliferation inhibi-
tion of PBMCs, whereas caused a slight down-
regulation of the population of Treg cells. Co- 
llectively, our results suggest that the combina-
tion can probably serve as promising candi-
dates for the development of novel therapeutic 
approaches for different types of breast can-
cer, especially TNBC.   
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Supplementary Materials
Establishment of MDA-MB-231 mouse xenografts, and the following administration of AsIII and Tetra, 
each alone or in combination, and the preparation of tumor tissues 
In vivo antitumor activity of AsIII alone or in combination with Tetra was studied using human breast 
cancer nude mouse xenograft model.  Five-week-old female immunodeficient BALB/c nude mice were 
obtained from Japan SLC, Inc. (Shizuoka, Japan) and housed at 23±1°C in a room with a constant 
humidity of 55±5% and a regular 12-h light/12-h dark cycle for several days. MDA-MB-231 cells (1×107, 
suspended in 0.1 ml phosphate-buffered saline (PBS)) were then injected subcutaneously into the right 
flank of each mouse. Tumors (visualized as a small nodule at the sites of injection) appeared approxi-
mately 5-7 days later after injection, and the mice were randomly divided into four groups (n=5) accord-
ing to body weight and tumor size using SPSS 21.0 software, and given the following treatments: vehi-
cle-control (treated with PBS); AsIII alone (2 mg/kg/day); Tetra alone (20 mg/kg/day); AsIII (2 mg/kg/
day)+Tetra (20 mg/kg/day). The mice were administered i.p. as described above once a day for 10 
weeks, respectively. The tumor size was measured every day in two perpendicular dimensions with ver-
nier calipers, and the tumor volume (TV) (mm3) was calculated by the formula: TV = length (mm) × width2 
(mm2) × 0.5. The body weights were also measured every day and were used as an indicator of systemic 
toxicity of the treatment. Throughout the experiment, the mice had free access to food and water accord-
ing to the National Institute of Health Guide for the Care and Use of Laboratory Animals and the Guidance 
for Experimental Animal Care issued by the Prime Minister’s Office of Japan. At the end of the treatment, 
all animals were sacrificed, and the tumors were removed, photographed and weighed.  Tumors were 
fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer or frozen in liquid nitrogen for further 
analysis. The study was approved by the Committee of Animal Care and Welfare of Tokyo University of 
Pharmacy and Life Sciences (Tokyo, Japan; registration no. P17-59). Tetrandrine hydrochloride injection, 
and arsenious acid and sodium chloride injection were obtained from Jiangxi Yintao Pharmaceutical 
Co., Ltd. (Jiangxi, China) and Heilongjiang Harbin Pharmaceutical Co., Ltd. (Heilongjiang, China), respec-
tively for the in vivo study.  
